Amphotericin B ( DrugBank: Amphotericin B )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis2

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02273661
(ClinicalTrials.gov)
November 19, 201422/10/2014Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)Allergic Bronchopulmonary AspergillosisDrug: Liposomal amphotericin B (Ambisome®);Drug: placeboPoitiers University HospitalNULLCompleted18 YearsN/AAll174Phase 2France
2EUCTR2010-019194-15-IT
(EUCTR)
12/05/201013/05/2010Esplorative study to evaluate the tolerability of Amphotericin B lipid complex (Abelcet) by aerosol in patients with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) - NDEsplorative study to evaluate the tolerability of Amphotericin B lipid complex (Abelcet) by aerosol in patients with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) - ND Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA)
MedDRA version: 9.1;Level: SOC;Classification code 10021881
MedDRA version: 9.1;Level: PT;Classification code 10011762
Trade Name: ABELCET
INN or Proposed INN: Amphotericin B
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy